The fact that Ras + Raf-inhibitor–-induced tumorigenesis requires both Raf-mediated Erk activation and kinase-independent Rok-α inhibition by C-Raf suggests that combination therapies targeting kinase and non-kinase functions of Raf may be more efficient and safer for the treatment of skin tumors. Here, RAF1 is linked to skin neoplasm.